ArticleThe Journal of antibiotics2023
A novel biologically active xylaphenoside from the endophytic fungus Xylaria CGMCC No.5410.
Article in The Journal of antibiotics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anticancer Activity of Demethylincisterol A3 and Related Incisterol-Type Fungal Products.Life (Basel, Switzerland) · 2025Review
- Structures and Biological Activities of Secondary Metabolites fromJournal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel 3,4-dihydroisocoumarin glycoside (1) was obtained from the culture of endophytic fungal Xylaria CGMCC No.5410 from the leaves of Selaginella moellendorffii Hieron, together with five known compounds (2-6). Their structures elucidations were conducted by HRESIMS, NMR and IR spectroscopic analysis. All the isolated compounds were evaluated for their antimicrobial, anti-tumor, and anti-HIV-1 activities. Compound 1 only displayed weak antimicrobial activity against micrococcus luteus. The other known compounds showed different antimicrobial, anti-tumor, or anti-HIV-1 activities.
Indexed as
Identifiers
36806196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.